Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496112 | 0.92 | JAK2 (0.49) | CHEK1JAK2JAK3KDRFLT1 | |
| SCHEMBL1496147 | 0.82 | CHEK1 (0.58) | CHEK1JAK2KDRFLT1IKBKB | |
| SCHEMBL1496105 | 0.81 | CHEK1 (0.54) | CHEK1JAK2JAK3KDRNTRK1 | |
| SCHEMBL1496033 | 0.81 | CHEK1 (0.58) | CHEK1KDRIKBKB | |
| SCHEMBL1496163 | 0.79 | CHEK1 (0.56) | CHEK1KDRFLT1IKBKB | |
| SCHEMBL1496143 | 0.78 | CHEK1 (0.58) | CHEK1KDRFLT1IKBKB | |
| SCHEMBL1496047 | 0.78 | CHEK1 (0.58) | CHEK1KDRFLT1IKBKB | |
| SCHEMBL12922000 | 0.78 | CHEK1 (0.47) | CHEK1NPC1RAB9AIKBKB | |
| SCHEMBL29900175 | 0.78 | CHEK1 (0.47) | CHEK1NPC1RAB9AIKBKB | |
| SCHEMBL1496162 | 0.76 | CHEK1 (0.49) | CHEK1JAK2KDRKMT2AFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | claimed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | claimed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | claimed |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | disclosed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | disclosed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021141974-A2 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021141980-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, DCK, CHEK2 | CHEK1 1/4885JAK2 1341/4885JAK3 1409/4885 |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, CHEK2, DCK | CHEK1 1/4885JAK2 1101/4885JAK3 1182/4885 |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885JAK2 839/4885JAK3 1174/4885 |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | CHEK1 2/4885JAK2 811/4885JAK3 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.